Earlier this week, Celltrion filed two petitions for inter partes review of Genentech’s U.S. Patent No. 6,407,213. According to Celltrion’s petitions, the patent is directed to humanized antibodies. Mylan previously challenged the same patent in two IPR petitions, which terminated in settlement with Genentech.
Blog Big Molecule Watch May 10, 2017